Excessive weight is one of the factors influencing the development and rapid progression of COPD that may be proved by the fact that weight loss leads to the decrease in the severity of clinical manifestations of this pathology.
The objective of the research work is to investigate the diagnostic value of TNF-α in progression of GOLD III COPD in patients with excessive body weight by studying its level in blood serum. To determine the dynamics of inflammatory response were examined 45 patients with overweight: 18 patients with stable phase of pathological process, and 27 patients at exacerbation phase. The control group involved 23 apparently healthy individuals (AHI).
It was estimated that the course of COPD GOLD III in overweight patients at exacerbation phase is accompanied by more pronounced manifestations of systemic inflammation, manifested by an increase in TNF-α levels by 1.5 times (p1˂0.001), compared with similar values in patients with stable phase and 2.3 times (p2˂0.001) from the values of the group of AHI, where its level was 265,79±4,95 ng / ml. After the complex therapy, there was a positive dynamics of leptin, the level of which on the 10th day decreased by 1.4 times (p1 ð ˂ 0.05) from values to treatment, which was 89,85±20,1ng / ml against 265,8 ± 22,3ng / ml. However, more positive results were observed after three months when used in complex therapy lifestyle modifications, where the level of this marker was (139,89±30,25) ng/ml, which is 1.9 times less than the values before treatment and 4.4 times the values of the AHI group.
The use of complex therapy using lifestyle modifications in the treatment of COPD GOLD III in overweight patients has a more positive effect on the indicators of inflammatory activity.
REFERENCES
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report . National Heart, Lung, and Blood Institute. Update 2018.
2. Barnes P.J. Systemic manifestations and comorbiditiesof COPD/ P.J. Barnes, B.R. Celli // Eur. Respir. J. 2009.Vol. 33.P.1165–1185.
4. Dynamics of systemic inflammatory markers in case of exacerbation of COPD (III degree of bronchial obstruction) in overweight patients with the optimization of management and treatment/ N. V. Korzh, M. M. Ostrovskyy. // The Pharma Innovation Journal. – 2021. – ¹10. – Ñ. 9–13.
|
Ãîëîñóâàííÿ 
Öÿ ðîáîòà ë³öåíçóºòüñÿ â³äïîâ³äíî äî Creative Commons Attribution 4.0 International License
Çíàéøëè ïîìèëêó? Âèä³ë³òü ïîìèëêîâèé òåêñò ìèøêîþ ³ íàòèñí³òü Ctrl + Enter